Our Board

Dr. Katherine Matthay is the Mildred V. Strouss Professor of translational oncology at the University of California San Francisco, and is internationally known for her work in advancing therapy of neuroblastoma. She is the leader of the Pediatric Malignancies program in the Helen Diller Family Comprehensive Cancer Center at UCSF.  She served as North American continental president for the International Society of Pediatric Oncology, and is currently the president of the Advances in Neuroblastoma Research Association. She initiated several landmark randomized trials in neuroblastoma in the COG, improving outcome with high dose therapy and bone marrow transplant and with isotretinoin and then with antibody therapies. She established the NCI-funded NANT clinical trials consortium for targeted therapy of neuroblastoma, now in its third 5-year cycle.  She has been a leader in the development of targeted radiotherapy for neuroblastoma with the ¹³¹I-mIBG, which she initiated at UCSF in 1987. She cares for children with relapsed and resistant neuroblastoma from many corners of the world, providing new therapies to try to overcome tumor resistance.

Dr. W. Clay Gustafson is a pediatric cancer specialist in the Children's Cancer and Blood Disease Program at UCSF Benioff Children's Hospital. He is a physician scientist with a laboratory interest in developing novel therapeutics for pediatric solid tumors, particularly neuroblastoma. His focus is on designing therapies to target the MYC family of proteins, which are critical to cancer biology and potentially an “achiles heel” in neuroblastoma. Clinically, he cares primarily for children with relapsed and refractory neuroblastoma with a focus on emerging therapies.